Jennifer B Green, Brendan M Everett, Alokananda Ghosh, Naji Younes, Heidi Krause-Steinrauf, Joshua Barzilay, Cyrus Desouza, Silvio E Inzucchi, Yashashwi Pokharel, David Schade, Alexandra Scrymgeour, Meng H Tan, Kristina M Utzschneider, Sunder Mudaliar
BACKGROUND: Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2 diabetes and low cardiovascular risk are unclear. We investigated cardiovascular outcomes by treatment group in participants randomly assigned to insulin glargine, glimepiride, liraglutide, or sitagliptin, added to baseline metformin, in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)...
March 26, 2024: Circulation